NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis
USA - NASDAQ:NBIX - US64125C1099 - Common Stock
137.73 USD
+0.5 (+0.36%)
137.73 USD
0 (0%)
Overall NBIX gets a fundamental rating of 7 out of 10. We evaluated NBIX against 536 industry peers in the Biotechnology industry. NBIX gets an excellent profitability rating and is at the same time showing great financial health properties. NBIX is not overvalued while it is showing excellent growth. This is an interesting combination. This makes NBIX very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
NBIX had positive earnings in the past year.
In the past year NBIX had a positive cash flow from operations.
Each year in the past 5 years NBIX has been profitable.
Each year in the past 5 years NBIX had a positive operating cash flow.
1.2 Ratios
NBIX has a Return On Assets of 8.95%. This is amongst the best in the industry. NBIX outperforms 93.47% of its industry peers.
NBIX has a Return On Equity of 12.93%. This is amongst the best in the industry. NBIX outperforms 93.84% of its industry peers.
NBIX has a Return On Invested Capital of 10.85%. This is amongst the best in the industry. NBIX outperforms 94.59% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is below the industry average of 15.49%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.95% | ||
| ROE | 12.93% | ||
| ROIC | 10.85% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
The Profit Margin of NBIX (13.88%) is better than 93.28% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
The Operating Margin of NBIX (19.89%) is better than 94.40% of its industry peers.
In the last couple of years the Operating Margin of NBIX has declined.
NBIX has a better Gross Margin (98.49%) than 97.39% of its industry peers.
In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.89% | ||
| PM (TTM) | 13.88% | ||
| GM | 98.49% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NBIX is creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
NBIX has an Altman-Z score of 8.30. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 8.30, NBIX belongs to the best of the industry, outperforming 80.78% of the companies in the same industry.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.3 |
ROIC/WACC1.16
WACC9.33%
2.3 Liquidity
NBIX has a Current Ratio of 3.20. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a worse Current ratio (3.20) than 62.50% of its industry peers.
NBIX has a Quick Ratio of 3.10. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a worse Quick ratio (3.10) than 60.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
NBIX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.11%.
The Earnings Per Share has been growing by 58.39% on average over the past years. This is a very strong growth
Looking at the last year, NBIX shows a quite strong growth in Revenue. The Revenue has grown by 18.42% in the last year.
The Revenue has been growing by 24.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.11%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%68.25%
Revenue 1Y (TTM)18.42%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%16.49%
3.2 Future
The Earnings Per Share is expected to grow by 36.58% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 12.22% on average over the next years. This is quite good.
EPS Next Y37.76%
EPS Next 2Y41.82%
EPS Next 3Y37.15%
EPS Next 5Y36.58%
Revenue Next Year18.64%
Revenue Next 2Y16.67%
Revenue Next 3Y14.97%
Revenue Next 5Y12.22%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.75 indicates a quite expensive valuation of NBIX.
NBIX's Price/Earnings ratio is rather cheap when compared to the industry. NBIX is cheaper than 92.16% of the companies in the same industry.
NBIX is valuated rather expensively when we compare the Price/Earnings ratio to 27.55, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 20.81, which indicates a rather expensive current valuation of NBIX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.72% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.04, NBIX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.75 | ||
| Fwd PE | 20.81 |
4.2 Price Multiples
NBIX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NBIX is cheaper than 93.28% of the companies in the same industry.
NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.84 | ||
| EV/EBITDA | 22.6 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 37.15% in the coming years.
PEG (NY)1.08
PEG (5Y)0.7
EPS Next 2Y41.82%
EPS Next 3Y37.15%
5. Dividend
5.1 Amount
No dividends for NBIX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
137.73
+0.5 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.77%
Inst Owner Change-0.05%
Ins Owners1.01%
Ins Owner Change0.59%
Market Cap13.66B
Analysts83.53
Price Target169.88 (23.34%)
Short Float %4.23%
Short Ratio4.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-39.31%
Min EPS beat(2)-85.62%
Max EPS beat(2)7%
EPS beat(4)1
Avg EPS beat(4)-33.29%
Min EPS beat(4)-85.62%
Max EPS beat(4)7%
EPS beat(8)2
Avg EPS beat(8)-28.41%
EPS beat(12)3
Avg EPS beat(12)-78.74%
EPS beat(16)4
Avg EPS beat(16)-77.91%
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-0.14%
Max Revenue beat(2)3.28%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)3.28%
Revenue beat(8)4
Avg Revenue beat(8)1.07%
Revenue beat(12)6
Avg Revenue beat(12)0.68%
Revenue beat(16)8
Avg Revenue beat(16)0.67%
PT rev (1m)0.71%
PT rev (3m)5.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.98%
EPS NY rev (1m)0.3%
EPS NY rev (3m)13.13%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)3.78%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)3.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.75 | ||
| Fwd PE | 20.81 | ||
| P/S | 5.44 | ||
| P/FCF | 25.84 | ||
| P/OCF | 24.08 | ||
| P/B | 5.07 | ||
| P/tB | 5.14 | ||
| EV/EBITDA | 22.6 |
EPS(TTM)3.38
EY2.45%
EPS(NY)6.62
Fwd EY4.8%
FCF(TTM)5.33
FCFY3.87%
OCF(TTM)5.72
OCFY4.15%
SpS25.31
BVpS27.17
TBVpS26.79
PEG (NY)1.08
PEG (5Y)0.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.95% | ||
| ROE | 12.93% | ||
| ROCE | 14.93% | ||
| ROIC | 10.85% | ||
| ROICexc | 15.33% | ||
| ROICexgc | 15.57% | ||
| OM | 19.89% | ||
| PM (TTM) | 13.88% | ||
| GM | 98.49% | ||
| FCFM | 21.06% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexcg growth 3Y35.59%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score7
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 135.44% | ||
| Cap/Sales | 1.54% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 107.53% | ||
| Profit Quality | 151.79% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 8.3 |
F-Score7
WACC9.33%
ROIC/WACC1.16
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)2.11%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%68.25%
EPS Next Y37.76%
EPS Next 2Y41.82%
EPS Next 3Y37.15%
EPS Next 5Y36.58%
Revenue 1Y (TTM)18.42%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%16.49%
Revenue Next Year18.64%
Revenue Next 2Y16.67%
Revenue Next 3Y14.97%
Revenue Next 5Y12.22%
EBIT growth 1Y-8.37%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year2.32%
EBIT Next 3Y23.13%
EBIT Next 5Y19.85%
FCF growth 1Y88.28%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y91.53%
OCF growth 3Y32.41%
OCF growth 5Y31.38%